Clinical trials: Necrotising Enterocolitis Neonatal
Prematurity Complications
Gut Permeability and Microbiome in Preterm Infants
NEC, a life-threatening, GI emergency characterized by increased IP, affects approximately 7 to 10% of preterm neonates, and typically occurs within 7 to 14 days of birth with mortality as high as 30-50%.
- Trial name
- NCT07667049
- Testing
- measurement of intestinal permeability
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Maryland, Baltimore
Necrotizing Enterocolitis of Newborn, Feeding Intolerance
Impact of Enteral Feeding on Splanchnic Oxygenation During Packed Red Blood Cell Transfusion in Preterm Infants
This clinical trial aims to learn if enteral feeding influences cerebral and splanchnic oxygenation during red blood cell infusion in very low birth-weight preterm infants.
- Conditions
- Necrotizing Enterocolitis of Newborn, Feeding Intolerance, PreTerm Neonate, Transfusion Related Complications
- Trial name
- TANEC (NCT06632314)
- Testing
- Enteral feeding
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Akdeniz University
Enterocolitis, Necrotizing, Infant, Premature
Role of Urinary Claudin-2, Caveolin-1, and EGF as Diagnostic Biomarkers of Necrotizing Enterocolitis in Preterm Neonates
Our study aims to determine the differences in the concentration of urinary claudin-2, caveolin-1, and epidermal growth factor (EGF) as non-invasive biomarkers in the diagnosis of Necrotizing Enterocolitis (NEC).
- Trial name
- NCT05335577
- Testing
- Urinary Claudin-2, Urinary Caveolin-1, Urinary EGF
- Where
- Indonesia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Brawijaya
Necrotizing Enterocolitis
Pentoxifylline in the Treatment of NEC in Premature Neonates
Pentoxifylline improves microcirculation and decreases TNF alpha levels associated with sepsis, rendering it of potential therapeutic value in necrotizing enterocolitis in premature neonates.
- Trial name
- NCT00271336
- Testing
- Pentoxifylline
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Shaare Zedek Medical Center
NEC, Necrotizing Enterocolitis
Study of Normal Intestinal Development and Disease in Premature and Term Neonates
Current research on early intestinal development is primarily performed in mouse models. While useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs…
- Conditions
- NEC, Necrotizing Enterocolitis, Intestinal Disease, Human Development
- Trial name
- NiiCE (NCT06681129)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Children's Hospital
Necrotizing Enterocolitis
Early Predictors of Necrotizing Enterocolitis in Neonates
The goal of this project is to identify neonates who are predisposed to Necrotizing Enterocolitis (NEC). the investigators will determine the effectiveness of non-invasive measures as well as biochemical markers to identify…
- Trial name
- NCT03210831
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Necrotizing Enterocolitis (NEC)
NETs: Protection or Harm in Neonatal Inflammation or Infection
This is a prospective in vitro cell biology study of polymorphonuclear leukocyte (PMN) protein synthesis in response to PAF. PMNs from cord blood of premature human infants at risk for NEC (birth weight between 501 - 1500 grams)…
- Trial name
- NCT00747851
- Where
- United States
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- University of Utah
Neonatal Disease
Intestinal Genes Expression Associated With Necrotizing Enterocolitis
In recent days, necrotizing enterocolitis is one of the most common and devastating problem in preterm infants. Therefore, it became a high growing research topic in the last decade.
- Trial name
- NCT04073342
- Testing
- Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
- Volunteers
- 1 people
- Sponsor
- Assiut University
Premature Intestinal Microbiota, Necrotizing Enterocolitis
Defining the Intestinal Microbiota in Premature Neonates
The investigators will collect daily faecal samples from premature (<32 weeks) infants in the intensive care unit from the day of birth until they are discharged.
- Conditions
- Premature Intestinal Microbiota, Necrotizing Enterocolitis, Late Onset Bloodstream Infection
- Trial name
- NCT01102738
- Where
- 3 sites in United Kingdom
- Volunteers
- 369 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Necrotizing Enterocolitis
Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis
Hypothesis: Controlled hypothermia to 33.5C for 48 hours reduces the severity of critical illness in neonates with severe necrotizing enterocolitis.
- Trial name
- CoolNEC (NCT01330576)
- Testing
- cooling blanket/mattress, Standard treatment of care at normothermia
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Bloody Stool, Necrotizing Enterocolitis
a Clinical Risk Score to Predict Bloody Stool in Neonates
Bloody stool is a main focus in non-neonatal intensive care unit ward, and it is one of the risk factors in neonates with subsequent necrotizing enterocolitis(NEC) and usually lead to longed duration of hospitalization.
- Trial name
- NCT05055817
- Testing
- bloody stool group, non-bloody stool group
- Where
- China
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Patent Ductus Arteriosus, Surgery
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach.
- Conditions
- Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
- Trial name
- PDA:TOLERATE (NCT01958320)
- Testing
- pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID
- Where
- 18 sites in United States, Sweden and 2 more
- Volunteers
- 202 people
- Sponsor
- University of California, San Francisco